14/15 June 2021
On 19 March 2021, the Swiss parliament approved amendments to the Swiss Narcotics Act. Among other things, this amendment stipulates that cannabis-based treatments can be prescribed directly by a doctor without having to obtain an exceptional authorization from the Swiss Federal Office of Public Health.
In Switzerland, cannabis is currently considered as an illegal narcotic and is subject to a comprehensive traffic prohibition. Consequently, cannabis may not be cultivated, produced, imported, exported or distributed. At present, the medical use of cannabis is therefore only possible to a limited extent and with an exceptional authorization from the Swiss Federal Office of Public Health. Sativex® is currently the only cannabis medicinal product authorized under medicinal product law in Switzerland. (Article in German)
Products with cannabidiol (CBD) are also en vogue in Switzerland. Unlike THC (tetrahydrocannabinol), CBD is not subject to the Swiss Narcotics Act. However, this does not mean that CBD can be added to products in Switzerland as desired or advertised arbitrarily. Swissmedic has therefore prepared a fact sheet on the various offers of raw materials and products containing CBD and their classification and marketability based on the current legal situation. The fact sheet serves primarily as a guide to the responsibilities of the relevant authorities. In addition, suppliers should be informed about the legal requirements to be observed.
The demand for treatment with cannabis has risen considerably in Switzerland. In order to facilitate the use of medicinal cannabis, the current prohibition in the Swiss Narcotics Act is to be lifted. (Article in German)
The following changes are to be made: